Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: StockDoc who wrote (784)	3/31/1998 8:10:00 AM
From: BD	Read Replies (1) \| Respond to of 887

Nobody has mentioned what Chiron's part may have been in this. Chiron is certainly knowlegable more so than Depo on NDA filings. I suspect however that each is quite different and very complex. I remember John Longnecker when he was with SCIO several years ago. They were developing a drug for acute renal failure known as ANP. Unfortuantly it failed two phase III and the company discontinued development of it. The company however did a good job testing, evalluation and in disclosing test results quickly then moving on to the next project.

To: StockDoc who wrote (784)	3/31/1998 11:53:00 AM
From: techbull	Read Replies (2) \| Respond to of 887

As far as I know with the steroids, it reduced the occurance and most patients did not have headaches so bad they wanted to drop out of the study. Dr Kim (if that is who you are talking about) also left. Ms Paradiso was in charge of clinical trials and it was percieved that she was the scape-goat for WALL STREET. Besides, why put a DVM in charge of human trials (even though DVM know more about animal physiology)? As well as if there was something she missed and didn't tell anyone. I don't know Mr Longenecker any differently than Mr. Erickson. But he seems to be going forward with the help of the main venture capitalist who took over temp as acting CEO. You know, I never heard who actually gave the presentation, I was just surprised that Depo didn't do their homework a bit better. They sent practically everyone else in top mgt, why not him. It is my impression that Chiron has not been involved much beyond funding the initial research and agreeing to the joint venture. Other than this, I haven't heard much.